Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280738 | 0.86 | GABRA2 (0.38) | PDE2ARAPGEF4KMT2AGABRA2GABRB2 | |
| SCHEMBL22310458 | 0.83 | KMT2A (0.33) | PDE2AKMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23689911 | 0.82 | AR (0.42) | PDE2ARAPGEF4GABRA2GABRB2GABRB3 | |
| SCHEMBL27749033 | 0.79 | METAP2 (0.41) | GABRA2GABRB2KIF11MAPTGABRB3 | |
| SCHEMBL9952880 | 0.79 | ALDH1A1 (0.60) | KMT2AMAPTMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL9725591 | 0.77 | PDE2A (0.40) | PDE2ARAPGEF4GPR35GABRA2GABRB2 | |
| SCHEMBL241686 | 0.77 | ALDH1A1 (0.42) | PDE2ARAPGEF4GPR35KMT2AGABRA2 | |
| SCHEMBL12864135 | 0.77 | GABRB3 (0.36) | PDE2ARAPGEF4KMT2AMAPTGABRB3 | |
| SCHEMBL16320650 | 0.77 | GABRA2 (0.38) | PDE2ARAPGEF4KMT2AGABRA2GABRB2 | |
| SCHEMBL14044235 | 0.77 | RAPGEF4 (0.33) | PDE2ARAPGEF4KMT2AGABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186227-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| EP-3792251-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Elanco Tiergesundheit AG (CH) | 2021-03-17 | — | — | EP | disclosed |
| EP-3702355-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS CONTAINING PYRIMIDINE, THE PREPARATION AND APPLICATION THEREOF | Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | ELANCO TIERGESUNDHEIT AG (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2017-08-10 | — | — | US | disclosed |
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2017-08-10 | — | — | US | disclosed |
| WO-2016033341-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-2990403-A1 | ANTHRANILAMIDES, SULFONAMIDES AND NITRO ANALOGUES DERIVED THEREFROM AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2016-03-02 | — | — | EP | disclosed |
| WO-2011058577-A1 | PROCESS FOR SYNTHESIZING POLYHALOGENATED PERHALOALKYLANILINE COMPOUNDS | GHARDA KEKI HORMUSJI (IN) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058577-A1 | PROCESS FOR SYNTHESIZING POLYHALOGENATED PERHALOALKYLANILINE COMPOUNDS | GHARDA KEKI HORMUSJI (IN) | 2011-05-19 | — | — | WO | disclosed |
| US-5616810-A | DEALKYLATION BY REACTING AN N-ALKYL OF N,N-DIALKYL ANILINE WITH AMMONIA OR A PRIMARY OR SECONDARY AMINE USING A PYRIDINE SALT CATALYST | RHONE-POULENC CHIMIE (FR) | 1997-04-01 | — | — | US | disclosed |
| US-5401882-A | Reaction of halobenzenes with dialkyl amide to form dialkyl anilines, dealkylation | RHONE-POULENC CHIMIE (FR) | 1995-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | PDE2A 1241/4885RAPGEF4 4352/4885GPR35 1353/4885 |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | PKD2, CATSPER1, ATP1B2 | PDE2A 1108/4885RAPGEF4 4479/4885GPR35 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.